Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial
D van der Heijde, A Kivitz, MH Schiff… - … : Official Journal of …, 2006 - Wiley Online Library
Objective To evaluate the safety and efficacy of adalimumab, a fully human recombinant
IgG1 monoclonal antibody that specifically targets human tumor necrosis factor, in patients …
IgG1 monoclonal antibody that specifically targets human tumor necrosis factor, in patients …
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
JC Davis Jr, D Van Der Heijde, J Braun… - Arthritis & …, 2003 - Wiley Online Library
Objective To determine the safety and efficacy of etanercept in a multicenter, randomized,
placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing …
placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing …
[HTML][HTML] Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α
JD Gorman, KE Sack, JC Davis Jr - New England Journal of …, 2002 - Mass Medical Soc
Background There are few effective treatments for ankylosing spondylitis, which causes
substantial morbidity. Because of the central role of tumor necrosis factor α in the …
substantial morbidity. Because of the central role of tumor necrosis factor α in the …
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double‐blind, placebo‐controlled, phase III trial
RD Inman, JC Davis Jr, DVD Heijde… - … : Official Journal of …, 2008 - Wiley Online Library
Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing
spondylitis (AS) in the GO‐RAISE study. Methods Patients with active AS, a Bath AS Disease …
spondylitis (AS) in the GO‐RAISE study. Methods Patients with active AS, a Bath AS Disease …
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: a randomized, double‐blind, placebo‐controlled trial
KC Kalunian, JC Davis Jr, JT Merrill… - Arthritis & …, 2002 - Wiley Online Library
Objective To evaluate the safety and efficacy of a humanized monoclonal antibody against
CD154 (IDEC‐131) in patients with active systemic lupus erythematosus (SLE). Methods In …
CD154 (IDEC‐131) in patients with active systemic lupus erythematosus (SLE). Methods In …
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
JD Finkielman, AS Lee, AM Hummel, MA Viss… - The American journal of …, 2007 - Elsevier
BACKGROUND: The pathogenic significance of antineutrophilic cytoplasmic antibodies
(ANCA) in Wegener's granulomatosis is controversial. Their presence is influenced by the …
(ANCA) in Wegener's granulomatosis is controversial. Their presence is influenced by the …
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis …
PA Merkel, GH Lo, JT Holbrook, AK Tibbs… - Annals of internal …, 2005 - acpjournals.org
Background: Venous thrombotic events (VTEs) have been observed in Wegener
granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of …
granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of …
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis
JD Finkielman, PA Merkel, D Schroeder… - Annals of internal …, 2007 - acpjournals.org
Background: The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the
management of patients with Wegener granulomatosis remains controversial. Objective: To …
management of patients with Wegener granulomatosis remains controversial. Objective: To …
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis
Objective To create a prognostic tool to quantify the 5‐year cardiovascular (CV) risk in
patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis …
patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis …
[PDF][PDF] Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody–associated vasculitis
Objective To identify risk alleles relevant to the causal and biologic mechanisms of
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods A …
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods A …